Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects (COG0108)

Cognition Therapeutics

Status and phase: Completed; Phase 1

Conditions: Alzheimer Disease

Treatments: Drug: 300 mg [C14] CT1812

Study type: Interventional

Funder types: Industry; NIH

Identifiers

NCT05225389

SB1AG073028 (U.S. NIH Grant/Contract)

COG0108

Details and patient eligibility

About

Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812

Full description

Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812 in 8 healthy male subjects

Subjects will be screened 28-days prior to dosing to determine eligibility.

Eligible subjects will be admitted to the clinical research unit (CRU) on Day -1. On Day 1, subjects will receive a single dose of CT1812 with a microtracer dose of [14C] CT1812. Whole blood, plasma, urine and fecal samples will be collection during the confinement period. Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.

Subjects will be and discharged from the CRU following completion of procedures 168 hours post dose (Day 8)

Enrollment: 8 patients

Sex: Male

Ages: 19 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy, adult, male, 19 - 55 years of age
2. Male subjects must follow protocol specified contraception guidance as described in the protocol
3. Continuous non smoker who has not used tobacco/nicotine containing products for at least 3 months prior to dosing.
4. Body mass index (BMI) ≥18.0 and ≤30.0 kg/m2 at the Screening visit (subjects must not have experienced a weight loss or gain of >10% within 4 weeks of dosing).
5. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI/designee at the Screening visit.
6. History of a minimum of 1 bowel movement per day.
7. Able to swallow multiple capsules.
8. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

1. Evidence of disease that, in the opinion of the PI/designee, may influence the outcome of the study within 4 weeks before dosing

2. Clinically significant illness, in the opinion of the PI/designee, that requires medical treatment within 8 weeks prior to dosing, or a clinically significant infection that requires medical treatment within 4 weeks prior to dosing.

3. Any history of GI surgery that may affect PK profiles of CT1812

4. Has evidence of a clinically significant abnormality in physical examination findings, vital signs, or clinical laboratory determinations at the Screening visit or Check-in.

5. Has a clinically significant ECG abnormality at the Screening visit or Check-in.

6. Estimated creatinine clearance <80 ml/min/1.73 m2 at the Screening visit.

7. Known history of clinically significant allergy to CT1812 or excipients at the Screening visit.

8. Has been diagnosed with acquired immune deficiency syndrome, or tests positive for human immunodeficiency virus (HIV), Hepatitis B virus surface antigen (HBsAg), or Hepatitis C virus (HCV) at the Screening visit.

9. Has a history of alcohol use disorder within the 2 years before the Screening visit.

10. Positive urine drug or alcohol results at the Screening visit or Check in.

11. Positive cotinine result at the Screening visit.

12. Unable to refrain from or anticipates the use of:

    • Any drugs, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to dosing except for those allowed in the protocol
    • Any drugs known to be significant inducers of CYP2D6 and CYP3A4 for 28 days prior to dosing.

13. Donation of blood or significant blood loss within 56 days prior to dosing.

14. Plasma donation within 7 days prior to dosing.

15. Poor peripheral venous access.

16. Recent history (within 2 weeks of Day 1) of abnormal bowel movements, such as diarrhea, loose stools, or constipation.

17. Has exposure to significant diagnostic or therapeutic radiation (e.g., serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to Check-in.

18. Has participated in a radiolabeled drug study where exposures are known to the PI within the previous 3 months prior to admission to the clinic for this study or participated in a radiolabeled drug study where exposures are not known to the PI within the previous 6 months prior to admission to the clinic for this study.

19. Has previously participated in a CT1812 investigational study.

20. Evidence or history of active suicidal thoughts in the 6 months preceding the screening visit; or have a history of a suicide attempt in the previous 2 years, or more than 1 lifetime suicide attempt; or are at serious suicide risk per the PIs clinical judgment.

21. Has any condition that would, in the opinion of the PI/designee or Sponsor, make the subject unsuitable for the study or is, in the opinion of the PI/designee, not likely to complete the study for any reason.

22. Participation in another clinical study within 30 days prior to dosing.

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

CT1812

Experimental group

Description:

Investigational Drug

Treatment:

Drug: 300 mg [C14] CT1812